By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – NextPharma will manufacture Epigenomics' colon cancer test for certain markets worldwide, the firms announced today.

Under terms of the deal, NextPharma will manufacture Epigenomics' Epi proColon test kit in Europe and other markets and will manufacture a cGMP-compliant version of the test, which is currently under development, for the US market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.